TY - JOUR
T1 - Chromosome Patterns of Human Leukocyte Established Cell Lines
AU - Miles, C. P.
AU - O'Neill, F.
AU - Armstrong, D.
AU - Clarkson, B.
AU - Keane, J.
PY - 1968/3/1
Y1 - 1968/3/1
N2 - Of 14 lines of human leukocytes, designated LK1D, LK57, LK60, LK63, LK87A, LK91, SK-L1, SK-L3, SK-L4, SK-L5, SK-L6, SK-L7, RPMI 7216, and RPMI 7466, all were classically diploid or very near-diploid when first examined. All but one showed occasional No. 10 chromosomes with the near terminal secondary constriction seen in Burkitt lymphoma cells in vitro. Nine lines showed accentuation of secondary constrictions at the usual sites on Chromosomes No. 1 and/or No. 16. Exchanges often occurred at these sites. Some cells in various lines showed multiple secondary constrictions or fragmentation (pulverization), but these and other chromosome abnormalities were in lower incidence than in Burkitt lymphoma strains. Many of the abnormalities in these lines may reflect underlying abnormalities of nucleoli or of nucleolar-associated heterochromatin.
AB - Of 14 lines of human leukocytes, designated LK1D, LK57, LK60, LK63, LK87A, LK91, SK-L1, SK-L3, SK-L4, SK-L5, SK-L6, SK-L7, RPMI 7216, and RPMI 7466, all were classically diploid or very near-diploid when first examined. All but one showed occasional No. 10 chromosomes with the near terminal secondary constriction seen in Burkitt lymphoma cells in vitro. Nine lines showed accentuation of secondary constrictions at the usual sites on Chromosomes No. 1 and/or No. 16. Exchanges often occurred at these sites. Some cells in various lines showed multiple secondary constrictions or fragmentation (pulverization), but these and other chromosome abnormalities were in lower incidence than in Burkitt lymphoma strains. Many of the abnormalities in these lines may reflect underlying abnormalities of nucleoli or of nucleolar-associated heterochromatin.
UR - http://www.scopus.com/inward/record.url?scp=0014260189&partnerID=8YFLogxK
M3 - Article
C2 - 5640868
AN - SCOPUS:0014260189
SN - 0008-5472
VL - 28
SP - 481
EP - 490
JO - Cancer Research
JF - Cancer Research
IS - 3
ER -